Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

ACADIA Pharmaceuticals Inc (NASDAQ:ACAD)

36.55
Delayed Data
As of Jul 22
 +0.49 / +1.36%
Today’s Change
16.64
Today|||52-Week Range
50.40
+2.52%
Year-to-Date
Investors Scour Big Pharma M&A Scene for Next Big Takeover
Jul 21 / TheStreet.com - Paid Partner Content
This Could Be the Next Big Pharma Buyout
Jul 18 / MotleyFool.com - Paid Partner Content
Strong On High Relative Volume: ACADIA Pharmaceuticals (ACAD)
Jul 20 / TheStreet.com - Paid Partner Content
3 Risky Biotech Stocks That Could Make You Rich
Jul 12 / MotleyFool.com - Paid Partner Content

Today’s Trading

Previous close36.06
Today’s open36.35
Day’s range35.65 - 37.06
Volume1,522,494
Average volume (3 months)3,125,469
Market cap$4.1B
Dividend yield--
Data as of 3:59pm ET, 07/22/2016

Growth & Valuation

Earnings growth (last year)-71.58%
Earnings growth (this year)-8.51%
Earnings growth (next 5 years)+18.27%
Revenue growth (last year)-49.17%
P/E ratioNM
Price/Sales58,810.80
Price/Book18.65

Competitors

 Today’s
change
Today’s
% change
NBIXNeurocrine Bioscienc...+0.43+0.88%
GRFSGrifols SA+0.04+0.24%
ENDPEndo International P...-0.50-2.78%
ICPTIntercept Pharmaceut...+5.04+3.29%
Data as of 3:59pm ET, 07/22/2016

Financials

Next reporting dateAugust 2, 2016
EPS forecast (this quarter)-$0.48
Annual revenue (last year)$61.0K
Annual profit (last year)-$164.4M
Net profit margin-269,578.69%

Profile

Sector
Health Technology
Industry
Biotechnology
President, Chief Executive Officer &
Director
Stephen R. Davis
Vice President-Technology Development &
Operations
James A. Nash
Corporate headquarters
San Diego, California

Forecasts

Partner Offers

Search for Jobs